I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...

The STRIDE trial evaluates the impact of semaglutide ... trading quite close to the 2-year historical minimums. I see that Novo Nordisk is cheaper than its main competitor, Eli Lilly, when ...

Glox Therapeutics has appointed of Michael Murray as chair of its board. He will work with the leadership team to accelerate ...

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring ...

At the time, the drugs had sent the two pharma companies to the top of their respective worlds: Novo Nordisk became the ... only hit its stride in 2021, but snack makers were underperforming ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...